{"DataElement":{"publicId":"4662316","version":"1","preferredName":"Prior Therapeutic Procedure Fulvestrant Everolimus Administered Stratification Type","preferredDefinition":"The stratification factor related to the prior administration of fulvestrant and/or everolimus.","longName":"PRIFULVEVERTYPE","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"4662283","version":"1","preferredName":"Prior Therapeutic Procedure Fulvestrant Everolimus Administered","preferredDefinition":"Information related to the prior administration of fulvestrant and/or everolimus.","longName":"PRIFULVEVER","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"3693401","version":"1","preferredName":"Prior Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D743B17B-E51D-394C-E040-BB89AD4312FF","latestVersionIndicator":"Yes","beginDate":"2013-03-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2013-03-06","modifiedBy":"ONEDATA","dateModified":"2013-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4662270","version":"1","preferredName":"Fulvestrant Everolimus Administered","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04):A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05):The act of having given something (e.g., a medication or test).","longName":"C1379:C48387:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C7823C1-FD74-15FF-E050-BB89AD431F62","latestVersionIndicator":"Yes","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"ONEDATA","dateModified":"2015-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C7823C1-FD85-15FF-E050-BB89AD431F62","latestVersionIndicator":"Yes","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4662292","version":"1","preferredName":"Prior Therapy Fulvestrant Everolimus Stratification Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"PRIFULVEVERTYPE","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Prior fulvestrant or everolimus or both","valueDescription":"Prior fulvestrant or everolimus or both","ValueMeaning":{"publicId":"4662294","version":"1","preferredName":"Prior fulvestrant or everolimus or both","longName":"4662294","preferredDefinition":"Prior fulvestrant or everolimus or both","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C782F51-9D84-AD56-E050-BB89AD430D86","latestVersionIndicator":"Yes","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0C782F51-9D9D-AD56-E050-BB89AD430D86","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"ONEDATA","dateModified":"2015-01-12","deletedIndicator":"No"},{"value":"No prior fulvestrant and no prior everolimus","valueDescription":"No prior fulvestrant and no prior everolimus","ValueMeaning":{"publicId":"4662293","version":"1","preferredName":"No prior fulvestrant and no prior everolimus","longName":"4662293","preferredDefinition":"No prior fulvestrant and no prior everolimus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C782F51-9D61-AD56-E050-BB89AD430D86","latestVersionIndicator":"Yes","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0C782F51-9D7A-AD56-E050-BB89AD430D86","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"ONEDATA","dateModified":"2015-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C782F51-9D4D-AD56-E050-BB89AD430D86","latestVersionIndicator":"Yes","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"ZIEGLERK","dateModified":"2015-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior fulvestrant and/or ever","type":"Preferred Question Text","description":"Prior fulvestrant and/or everolimus","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C782F51-9DA7-AD56-E050-BB89AD430D86","latestVersionIndicator":"Yes","beginDate":"2015-01-12","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-01-12","modifiedBy":"ZIEGLERK","dateModified":"2015-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}